EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

Matthew Matasar iD, Zhiming Li, Theodoros P Vassilakopoulos iD, Juan-Manuel Sancho iD, Andreas Viardot iD, Andrew McMillan, Mehmet Sinan Dal, Juliana Pereira iD, Jin Seok Kim iD, Lugui Qiu, Connie Lee Batlevi iD, Rania Ibrahim und 7 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-25-02849 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Matthew Matasar und 18 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Cancer Institute, New Brunswick, NJ. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Lymphoma, Large B-Cell, Diffuse, Rituximab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) face an unfavorable prognosis once first-line treatment fails; therefore, there is an unmet need for new treatment options. We evaluated the efficacy and safety of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (Pola-R-GemOx) as an alternative therapy in patients with transplant-ineligible R/R DLBCL. METHODS The phase III POLARGO trial was a randomized, open-label, global study. Following a Pola-R-GemOx safety run-in (n = 15), patients with R/R DLBCL (not otherwise specified or transformed indolent lymphoma) ineligible for autologous stem cell transplant were randomly assigned 1:1 to receive Pola-R-GemOx or R-GemOx alone every 21 days for up to eight cycles. The primary end point was overall survival (OS). RESULTS In total, 255 patients were randomly assigned to receive Pola-R-GemOx (n = 129) or R-GemOx (n = 126). After a median follow-up of 24.6 months, patients receiving Pola-R-GemOx versus R-GemOx had a significantly lower risk of death (hazard ratio, 0.6 [95% CI, 0.43 to 0.83]; P = .0017) with a median OS of 19.5 months (95% CI, 13.3 to not estimable) versus 12.5 months (95% CI, 8.9 to 15.8). The most common grade 3/4 adverse events (AEs) were thrombocytopenia and neutropenia. Peripheral neuropathy was more common with Pola-R-GemOx (n = 73 [57%]) versus R-GemOx (n = 36 [29%]) and was primarily grade 1. Fatal AEs occurred in 15 (12%) and five (4%) patients in the Pola-R-GemOx and R-GemOx groups, respectively, and were largely driven by infections (including COVID-19). CONCLUSION Pola-R-GemOx significantly improved OS compared with R-GemOx, offering an additional treatment option in patients with transplant-ineligible R/R DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsDeoxycytidineLymphoma, Large B-Cell, DiffuseRituximabHumansFemaleOxaliplatinMaleAgedMiddle AgedAntibodies, MonoclonalGemcitabineAged, 80 and overAdultImmunoconjugates

Substanzen

DeoxycytidineRituximabOxaliplatinpolatuzumab vedotinAntibodies, MonoclonalGemcitabineImmunoconjugates

Autor:innen und Institutionen

  • Rutgers Cancer Institute, New Brunswick, NJ.
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
  • ICO-IJC-HU Germans Trias i Pujol, Barcelona, Spain.
  • Department of Internal Medicine III, University Hospital, Ulm, Germany.
  • Center for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.

ORCID-Profile: Matthew Matasar, Theodoros P Vassilakopoulos, Juan-Manuel Sancho, Andreas Viardot, Juliana Pereira, Jin Seok Kim, Connie Lee Batlevi, Will Harris

Zitieren

APA

Matasar, M., Li, Z., Vassilakopoulos, T. P., Sancho, J. M., Viardot, A., McMillan, A., Dal, M. S., Pereira, J., Kim, J. S., Qiu, L., Batlevi, C. L., Ibrahim, R., Hernandez, J., McCall, B., Jiang, Y., Yan, M., Harris, W., Musick, L., & Haioun, C. (2026). Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-02849

Vancouver

Matasar M, Li Z, Vassilakopoulos TP, Sancho JM, Viardot A, McMillan A, et al. Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-25-02849

BibTeX
@article{Matasar2026,
  author = {Matasar, Matthew and Li, Zhiming and Vassilakopoulos, Theodoros P and Sancho, Juan-Manuel and Viardot, Andreas and McMillan, Andrew and Dal, Mehmet Sinan and Pereira, Juliana and Kim, Jin Seok and Qiu, Lugui and Batlevi, Connie Lee and Ibrahim, Rania and Hernandez, Juana and McCall, Bruce and Jiang, Yanwen and Yan, Mark and Harris, Will and Musick, Lisa and Haioun, Corinne},
  title = {Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-25-02849}
}
Kostenlos starten →